These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 9213377)

  • 61. [Topics on eosinophilia-myalgia syndrome].
    Kamatani N
    Nihon Naika Gakkai Zasshi; 1991 Nov; 80(11):1782-7. PubMed ID: 1783846
    [No Abstract]   [Full Text] [Related]  

  • 62. Production of polyclonal antibodies against 1,1'-ethyliden bis[L-tryptophan] (EBT), a potential contaminant causing eosinophilia-myalgia syndrome (EMS).
    Kurihara N; Yanagisawa H; Jin Z; Wada O
    Toxicol Lett; 1993 Mar; 66(3):231-6. PubMed ID: 8475503
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Eosinophilia-myalgia syndrome in Germany: an epidemiologic review.
    Carr L; Rüther E; Berg PA; Lehnert H
    Mayo Clin Proc; 1994 Jul; 69(7):620-5. PubMed ID: 8015323
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Is there any relationship between eosinophilia myalgia syndrome (EMS) and fibromyalgia syndrome (FMS)? An analysis of clinical and immunological data.
    Barth H; Berg PA; Klein R
    Adv Exp Med Biol; 1999; 467():487-96. PubMed ID: 10721092
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Analysis of Centers for Disease Control and Prevention criteria for the eosinophilia-myalgia syndrome in a geographically defined population.
    Spitzer WO; Haggerty JL; Berkson L; Davis W; Palmer W; Tamblyn R; Laprise R; Mulder LJ
    J Rheumatol Suppl; 1996 Oct; 46():73-9; discussion 79-80. PubMed ID: 8895183
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A comparative study on antibodies to nucleoli and 5-hydroxytryptamine in patients with fibromyalgia syndrome and tryptophan-induced eosinophilia-myalgia syndrome.
    Klein R; Berg PA
    Clin Investig; 1994 Jul; 72(7):541-9. PubMed ID: 7981584
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Eosinophilia-myalgia syndrome in Wisconsin.
    Butler JC; Davis JP
    Wis Med J; 1990 Dec; 89(12):687-91. PubMed ID: 2293489
    [TBL] [Abstract][Full Text] [Related]  

  • 68. L-tryptophan-induced eosinophilia-myalgia syndrome. I. Report of two cases with pseudoxanthoma-elasticum-like skin changes.
    Mainetti C; Schmied E; Masouyé I; Chavaz P; Saurat JH
    Dermatologica; 1991; 183(1):57-61. PubMed ID: 1769422
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Once too little, now too much.
    Weber KT
    Cardiovasc Res; 1998 Jun; 38(3):541-4. PubMed ID: 9747424
    [No Abstract]   [Full Text] [Related]  

  • 70. [Eosinophilia-myalgia syndrome. Clinical aspects and follow-up of 10 patients].
    Mensing H; Schallreuter KU; Senff H; Steinkraus V
    Hautarzt; 1992 Jul; 43(7):436-40. PubMed ID: 1506202
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Detection of antineutrophil cytoplasmic antibody in a patient with L-tryptophan induced eosinophilia-myalgia syndrome.
    Cilursu AM; Goeken J; Olson RR
    Ann Rheum Dis; 1991 Nov; 50(11):817-9. PubMed ID: 1772299
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Increased type I collagen gene expression in L-tryptophan associated eosinophilia-myalgia syndrome skin fibroblasts.
    Varga J; Li L; Jimenez SA
    J Rheumatol; 1993 Aug; 20(8):1303-8. PubMed ID: 8230009
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Eosinophilia-myalgia syndrome associated with ingestion of L-tryptophan.
    Keating JP; Wardill K; Viggiano J
    N Z Med J; 1992 Aug; 105(939):317. PubMed ID: 1386918
    [No Abstract]   [Full Text] [Related]  

  • 74. Psychiatric aspects of the eosinophilia-myalgia syndrome.
    Epstein SA; Krahn L; Clauw DJ; Gomes AP; Weigert S; Goldberg RL
    Psychosomatics; 1995; 36(1):22-5. PubMed ID: 7871130
    [TBL] [Abstract][Full Text] [Related]  

  • 75. ["Eosinophilia-myalgia" syndrome due to L-tryptophan containing products. Cooperative evaluation of French Regional Centers of Pharmacovigilance. Analysis of 24 cases].
    Castot A; Bidault I; Bournerias I; Carlier P; Efthymiou ML
    Therapie; 1991; 46(5):355-65. PubMed ID: 1754978
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Eosinophilia-myalgia syndrome after L-tryptophan intake].
    Zillikens D; Bammel A; Lurz C; Elsner P; Burg G
    Hautarzt; 1991 Mar; 42(3):154-7. PubMed ID: 2055764
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Eosinophilia-myalgia syndrome in patients ingesting a single source of L-tryptophan.
    Henning KJ; Jean-Baptiste E; Singh T; Hill RH; Friedman SM
    J Rheumatol; 1993 Feb; 20(2):273-8. PubMed ID: 8474064
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A heretofore undisclosed crux of eosinophilia-myalgia syndrome: compromised histamine degradation.
    Smith MJ; Garrett RH
    Inflamm Res; 2005 Nov; 54(11):435-50. PubMed ID: 16307217
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Structural characterization of case-associated contaminants peak C and FF in L-tryptophan implicated in eosinophilia-myalgia syndrome.
    Naylor S; Williamson BL; Johnson KL; Gleich GJ
    Adv Exp Med Biol; 1999; 467():453-60. PubMed ID: 10721088
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The cause and pathogenesis of the eosinophilia-myalgia syndrome.
    Varga J; Uitto J; Jimenez SA
    Ann Intern Med; 1992 Jan; 116(2):140-7. PubMed ID: 1727618
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.